Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
This is a 28-day, placebo controlled clinical study assessing the safety, tolerability anti-inflammatory effect and pharmacokinetics of SB681323 in patients with COPD (Chronic Obstructive Pulmonary Disease).
Epistemonikos ID: f83bb4e52f0c0800c59e2e07cc0f71feeda86622
First added on: May 04, 2024